Drugs / [18F]FAPI-74
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07705074 | Aug 2026 → Sep 2029 expected | breast cancer, castration-resistant prostate carcinoma, endometriosis, fibrotic liver disease +12 | Martin Huellner | Not yet recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07285993 | Jun 2026 → Dec 2027 expected | invasive lobular breast carcinoma | Randy Yeh | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06503146 | Sep 2025 → Jun 2028 expected | cholangiocarcinoma, gastric cancer, hepatocellular carcinoma, mesothelioma +6 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06568783 | Dec 2024 → Oct 2027 expected | dermatomyositis | Farshad Moradi | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05641896 | Apr 2023 → Jun 2025 | cholangiocarcinoma, colorectal cancer, gastric cancer, hepatocellular carcinoma +1 | SOFIE | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07018661 | Jul 2025 → Jan 2028 expected | gastric adenocarcinoma | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07613099 | Jul 2026 → May 2031 expected | acute lung injury, disease related to hematopoietic stem cell transplant, pulmonary arterial hypertension, transplant-related bronchiolitis obliterans | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | No outcome recorded |
| Phase 3 | NCT07217717 | Dec 2025 → Dec 2027 expected | pancreatic ductal adenocarcinoma | SOFIE | Recruiting | No outcome recorded |
| Phase 3 | NCT07217704 | Nov 2025 → Aug 2027 expected | esophageal cancer, gastric cancer, gastroesophageal cancer | SOFIE | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]-FAPI-74 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07018661 ↗ |
| Known as | FAPI-74 | “[18F]FAPI-74 is a novel PET radiotracer that binds selectively to FAP, enabling visualization of fibroblast activity.” NCT07705074 ↗ |
| Action | Inhibit | “Radiolabeled fibroblast-activating protein inhibitors (FAPI), targeting stromal cancer-associated fibroblasts, are promising radiotracers.” PMID 41299326 ↗ Nov 2025 |
| Modality | Diagnostic / imaging agent | “radioactive diagnostic agent” NCT05641896 ↗ |
| Route | Intravenous | “intravenously” NCT05641896 ↗ |